MYXOFIBROSARCOMA
Clinical trials for MYXOFIBROSARCOMA explained in plain language.
Never miss a new study
Get alerted when new MYXOFIBROSARCOMA trials appear
Sign up with your email to follow new studies for MYXOFIBROSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis Phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults whose…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo attack on sarcoma aims to delay return of cancer
Disease control Recruiting nowThis study is for adults with high-risk soft tissue sarcoma that can be removed by surgery. It tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy, radiation, and surgery can delay the cancer from coming back. About 50 participants will receive the …
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to shrink sarcomas
Disease control Recruiting nowThis early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE1 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo targets sarcoma in limbs
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug pembrolizumab with chemotherapy drugs (melphalan and dactinomycin) delivered directly to the affected limb via isolated limb infusion can safely delay cancer growth. It enrolls 30 patients aged 12 and older with advanced s…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo aims to halt rare sarcomas
Disease control Recruiting nowThis study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced soft-tissue sarcoma that has spread. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and see if the treatment slows tumor grow…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for rare bone and soft tissue cancers
Disease control Recruiting nowThis study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC